Evidence map›Paper›PMID 25921660›Full record

ReviewClinics in liver disease2015

Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

Katherine A McGlynn, Jessica L Petrick, W Thomas London

2 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinics in liver disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 475 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
475citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03452553 nawithdrawnnot on this mapstarted 2018, after this paper: background citation

A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin

TypeinterventionalSponsorBoston Scientific CorporationRan2018 to 2020Enrolled0ConditionsHepatocellular Carcinoma (HCC)ArmsLC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
NCT03672305 early_phase1unknown statusnot on this mapstarted 2018, after this paper: background citation

Single-center, Open Clinical Study on the Efficacy and Safety of c-Met/PD-L1 Chimeric Antigen Receptor T Cell Injection in the Treatment of Primary Hepatocellular Carcinoma

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2018 to 2019Enrolled50ConditionsPrimary Hepatocellular CarcinomaArmsc-Met/PD-L1 CAR-T cell injection
3 · Its place in the literature

Who cites it

475 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Guideline
  2. Dysregulation of serum bile acids in liver cancer: a systematic review and meta-analysis.Metabolomics : Official journal of the Metabolomic Society · 2025
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Prediagnostic Plasma Metabolite Profiles and Prediction of Hepatocellular Carcinoma Risk: The Multiethnic Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  10. Observational
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

415 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892, USA. Electronic address: mcglynnk@mail.nih.gov.
Jessica L PetrickDivision of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892, USA.
W Thomas LondonFox Chase Cancer Center, Philadelphia, PA 19111, USA.

Funding

Studies of Rare CancersZIACP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MCGLYNN, KATHERINE · 2009 to 2025
$19.1M
Studies of Rare CancersZ01CP010158 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI BRINTON, LOUISE · 2001 to 2008
$2.4M
Intramural NIH HHS Z01 CP010158
6 · The paper itself

Abstract

Liver cancer is the second leading cause of global cancer mortality. The major risk factors for hepatocellular carcinoma (HCC) are being addressed with success by prevention efforts. Vaccination against hepatitis B virus has reduced incidence of HCC in Taiwan and is partly responsible for lower rates in China. New infections with hepatitis C virus are low in developed countries because of prevention of posttransfusion infections and reduced exposure to HCV by drug users. Aflatoxin exposure has been reduced by better grain storage and dietary changes. Obesity, metabolic syndrome, and diabetes are increasing in developed and developing countries and will lead to more cases of HCC.

Indexed as

ChemopreventionAfricaAsiaCarcinoma, HepatocellularEuropeGlobal HealthHumansIncidenceLiver NeoplasmsNorth AmericaOceaniaRisk FactorsSouth AmericaAflatoxinAlcoholChemopreventionCoffeeDiabetesHepatitis B virusHepatitis C virusIncidence

Identifiers

PMID25921660
PMCPMC4712629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.